Introduction: Endeavor® received FDA approval in 2008. Phases I, II, III, and IV of the Endeavor study were performed in Australia, New Zealand, Europe, and USA. The Endeavor Phase II study included a number of cases based in Asia, but not enough for a generalization of clinical data in Korea. A small study consisting of 99 patients was also performed in Japan. Furthermore, the medical policies of Japan differs from that of Korea in the case of stent indication. Methods: Between june 2006 and July 2007, 228 patients (148 male, mean age 60.5 years) in whom zotarolimus-eluting stent(ZES) were implanted were included in this study. The study follow-up period was 365 days from stent insertion. The clinical diagnoses of the study patients included 144 acute myocardial infarction, 54 unstable angina and 40 stable angina patients. The percentage of DM patients was 35% (80 case). All patient maintained anti-platelet therapy for a period of at least 9 months (aspirin, clopidogrel). Results: At 12 months, ZES had 11 MACE patients out of 228 patients(4.8%), including 4 patient deaths (1.8%), AMI 2 patients (0.9%), and TLR 5 patients (2.2%). MACEs were related to DM (P=0.03), but smoking, hypertension, hyperlipidemia, stent size or length, and stent implant site, were not related to MACEs. Conclusion: Despite varied clinical and angiographic characteristics, treatment with the ZES is associated with consistently low rates of TLR and overall major adverse events, including stent thrombosis. The result is similar to Endeavor Japan study.
|
